This presentation will discuss how the primary care provider provide care throughout the diagnostic workup and can manage difficult symptoms and avoid drug-drug interactions in hematology/oncology patients in tandem with the specialty provider. Nausea/vomiting and pain will be discussed as well as drug-drug interactions. | 1.0 CE/CME category 1 credits (0.75 Pharmacology) | $30.00

This session provides Advanced Practice Providers with an updated, practical overview of current trends and advancements in colorectal cancer (CRC) diagnosis and treatment. The presentation reviews evolving screening recommendations, including updates in stool-based testing, CT colonography, and enhanced detection strategies using colonoscopy. On the treatment side, the session highlights new systemic therapies, including immunotherapy options tumors, targeted therapies based on RAS/RAF status, and emerging agents for metastatic disease. | 1.0 CE/CME category 1 credits (0.50 Pharmacology) | $30.00

This session offers advanced practice providers an up-to-date overview of emerging developments in breast cancer diagnosis and treatment. Participants will review updates in staging, biomarker profiling, and the expanding role of precision medicine. On the treatment side, the session covers new systemic therapies, evolving indications for targeted agents such as CDK4/6 inhibitors, PARP inhibitors, and antibody-drug conjugates, as well as updates in endocrine therapy and immunotherapy. Changes in surgical and radiation approaches—particularly de-escalation strategies aimed at maintaining outcomes while reducing morbidity—will also be discussed. Practical guidance is provided to help APPs integrate these updates into clinical practice, enhance multidisciplinary coordination, and optimize patient education and survivorship care. By the end of the session, APPs will be better equipped to deliver evidence-based, patient-centered care in the rapidly evolving landscape of breast cancer management. | 1.0 CE/CME category 1 credits (0.75 Pharmacology) | $30.00

This talk will discuss the latest therapies and FDA approvals for melanoma. There will also be briedf discussion on management of side effects from these therapies. | 1.0 CE/CME category 1 credits (0.50 Pharmacology) | $30.00

This course will discuss how to assist the patient with coordination of care in the cancer patient. How to schedule testing, planning and also community resources will be discussed. Appointments and referrals can be a difficult task to coordinate. This speaker will discuss how to assist the patient on making this process easier and less stressful. | 1.0 CE/CME category 1 credits (0.00Pharmacology) | $27.50

This presentation will discuss how to screen and identify the at risk patient in the primary care setting.WIth special attention to the high risk populations. | 1.0 CE/CME category 1 credits (0.00 Pharmacology) | $27.50

This one-hour session will focus on the significant financial burden—often referred to as “financial toxicity”—experienced by patients undergoing cancer treatment. The discussion will explore the sources of this financial strain, its impact on patient outcomes and quality of life, and practical strategies for identifying patients at risk. Participants will also learn about available financial assistance programs, community resources, and institutional support services, along with guidance on how to effectively connect patients and families to these resources. | 1.0 CE/CME category 1 credits (0.25 Pharmacology) | $27.50

This presentation will introduce primary care providers to the mechanism of action of immunotherapies, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies and review several common immune-related adverse events. This presentation will also review the treatment of immune-related adverse events and offer best practices for primary care providers that co-manage patients with cancer. | 1.0 CE/CME category 1 credits (1.00 Pharmacology) | $27.50

This session provides Advanced Practice Providers with a practical and clinically focused review of the Complete Blood Count (CBC) and its interpretation. The presentation breaks down each component of the CBC—red blood cells, white blood cells, hemoglobin, hematocrit, platelets, and differential counts—explaining normal ranges, common abnormalities, and patterns that signal underlying disease. | 1.0 CE/CME category 1 credits (0.25 Pharmacology) | $30.00

"Supported by an educational grant from Merck" This session will provide an up-to-date review of current multigene panel testing options and possible outcomes for patients with cancer. We will also describe the published management recommendations for those with hereditary cancer predisposition. | 1.0 CE/CME category 1 credits (0.00 Pharmacology) | $30